Summary
1.13 0.01(0.89%)09/18/2024
Enzo Biochem, Inc. (ENZ)
Enzo Biochem, Inc. (ENZ)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
0.89 | 1.80 | 0.89 | 4.63 | -9.60 | -15.04 | -67.99 | 66.52 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 1.13 | |
Open | 1.11 | |
High | 1.14 | |
Low | 1.11 | |
Volume | 36,354 | |
Change | 0.01 | |
Change % | 0.89 | |
Avg Volume (20 Days) | 30,384 | |
Volume/Avg Volume (20 Days) Ratio | 1.20 | |
52 Week Range | 0.99 - 1.50 | |
Price vs 52 Week High | -24.67% | |
Price vs 52 Week Low | 14.14% | |
Range | 1.80 | |
Gap Up/Down | -0.02 |
Fundamentals | ||
Market Capitalization (Mln) | 57 | |
EBIDTA | -21,427,000 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 5.50 | |
Book Value | 1.4020 | |
Earnings Per Share | -0.4700 | |
EPS Estimate Current Quarter | 0.0000 | |
EPS Estimate Next Quarter | 0.0000 | |
EPS Estimate Current Year | 0.0000 | |
EPS Estimate Next Year | 0.0000 | |
Diluted EPS (TTM) | -0.4700 | |
Revenues | ||
Profit Marging | 0.9928 | |
Operating Marging (TTM) | -0.2555 | |
Return on asset (TTM) | -0.1653 | |
Return on equity (TTM) | -0.4501 | |
Revenue TTM | 32,803,000 | |
Revenue per share TTM | 0.6570 | |
Quarterly Revenue Growth (YOY) | 0.1380 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 11,566,000 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 0.8468 | |
Revenue Enterprise Value | 0.2096 | |
EBITDA Enterprise Value | -0.4220 | |
Shares | ||
Shares Outstanding | 51,225,700 | |
Shares Float | 39,348,023 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.02 | |
Insider (%) | 24.19 | |
Institutions (%) | 39.19 |
08/13 10:48 EST - reuters.com
Enzo Biochem to pay $4.5 mln for failing to safeguard patient data
Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.
Enzo Biochem to pay $4.5 mln for failing to safeguard patient data
Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.
07/17 00:49 EST - seekingalpha.com
Enzo Biochem: Is This Time Finally Different?
Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks.
Enzo Biochem: Is This Time Finally Different?
Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks.
06/20 09:46 EST - zacks.com
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.
06/14 14:20 EST - zacks.com
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions.
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions.
06/13 16:20 EST - globenewswire.com
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.
03/13 16:26 EST - globenewswire.com
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.
02/01 08:30 EST - globenewswire.com
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments.
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments.
12/15 16:20 EST - globenewswire.com
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023.
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023.
10/30 16:15 EST - globenewswire.com
Steven J. Pully Appointed to Enzo Biochem's Board of Directors
FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company's Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well.
Steven J. Pully Appointed to Enzo Biochem's Board of Directors
FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company's Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well.
10/26 01:18 EST - seekingalpha.com
Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares. Enzo's focus on generating positive cash flow and enhancing shareholder value could lead to significant improvement in Life Sciences results.
Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares. Enzo's focus on generating positive cash flow and enhancing shareholder value could lead to significant improvement in Life Sciences results.
09/06 08:30 EST - globenewswire.com
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo's Chief Operating Officer, Kara Cannon, assuming the role of interim CEO.
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo's Chief Operating Officer, Kara Cannon, assuming the role of interim CEO.
07/24 16:27 EST - globenewswire.com
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp
Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo's Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023.
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp
Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo's Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023.
06/14 19:21 EST - globenewswire.com
Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results
- Enzo Life Sciences reports revenue of $7.5 million, with margin improvement in Q3 FY23 FARMINGDALE, NY, June 14, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, today filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023 (Q3 FY23). Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period.
Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results
- Enzo Life Sciences reports revenue of $7.5 million, with margin improvement in Q3 FY23 FARMINGDALE, NY, June 14, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, today filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023 (Q3 FY23). Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period.
06/02 13:15 EST - businesswire.com
Federman & Sherwood Investigates Enzo Biochem for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #DataBreach--The law firm of Federman & Sherwood has initiated an investigation into Enzo Biochem with respect to their recent data breach. On May 30, 2023, Enzo Biochem notified 2.47 million patients that the company experienced a data breach after an unauthorized party accessed sensitive consumer data entrusted to the company. According to Enzo Biochem, they determined that information stored on their servers may have been subject to unauthorized access on April 6, 2023.
Federman & Sherwood Investigates Enzo Biochem for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #DataBreach--The law firm of Federman & Sherwood has initiated an investigation into Enzo Biochem with respect to their recent data breach. On May 30, 2023, Enzo Biochem notified 2.47 million patients that the company experienced a data breach after an unauthorized party accessed sensitive consumer data entrusted to the company. According to Enzo Biochem, they determined that information stored on their servers may have been subject to unauthorized access on April 6, 2023.
05/22 09:20 EST - globenewswire.com
Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale
FARMINGDALE, NY, May 22, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), announced today that the preliminary voting results from the Inspector of Election at today's Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo's outstanding common stock. Pending final results of the vote, Enzo will have obtained shareholder approval and met all regulatory requirements for closing the sale of substantially all of the operating assets and assignment of certain liabilities of Enzo's Clinical Labs division.
Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale
FARMINGDALE, NY, May 22, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), announced today that the preliminary voting results from the Inspector of Election at today's Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo's outstanding common stock. Pending final results of the vote, Enzo will have obtained shareholder approval and met all regulatory requirements for closing the sale of substantially all of the operating assets and assignment of certain liabilities of Enzo's Clinical Labs division.
05/02 20:30 EST - prnewswire.com
SHAREHOLDER ALERT: Weiss Law Investigates Enzo Biochem, Inc.
NEW YORK , May 2, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Enzo Biochem, Inc. ("Enzo Biochem" or the "Company") (NYSE: ENZ) in connection with its acquisition by Laboratory Corporation of America Holdings (NYSE: LH) ("Labcorp"). The transaction value is approximately $146 million.
SHAREHOLDER ALERT: Weiss Law Investigates Enzo Biochem, Inc.
NEW YORK , May 2, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Enzo Biochem, Inc. ("Enzo Biochem" or the "Company") (NYSE: ENZ) in connection with its acquisition by Laboratory Corporation of America Holdings (NYSE: LH) ("Labcorp"). The transaction value is approximately $146 million.
04/24 16:05 EST - globenewswire.com
Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders
FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the sale (the “Asset Sale”) of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”) and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the “Asset Purchase Agreement”), by and among the Company, Enzo Clinical Labs, Inc., a New York corporation and Labcorp will be held on May 22, 2023 at 9:00 a.m. Eastern Time.
Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders
FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the sale (the “Asset Sale”) of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”) and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the “Asset Purchase Agreement”), by and among the Company, Enzo Clinical Labs, Inc., a New York corporation and Labcorp will be held on May 22, 2023 at 9:00 a.m. Eastern Time.
03/21 09:43 EST - globenewswire.com
Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results
- Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division
Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results
- Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division
03/20 06:00 EST - pennystocks.com
Top Sectors to Explore for Penny Stocks to Buy
Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Sectors to Explore for Penny Stocks to Buy
Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
03/18 06:00 EST - pennystocks.com
Penny Stock Psychology: Developing a Winning Mindset
Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stock Psychology: Developing a Winning Mindset
Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.